Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.64 |
| ▸ | REN | P00797 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PEPD | P12955 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 3/20 | 0.58 |
| ▸ | FAP | Q12884 | 2/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7271951 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL152403 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL8316371 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL2115244 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL9164453 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL19824765 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| SCHEMBL593691 | 1.00 | ACE (0.64) | ACERENKDM4EF2LMNA | |
| Hydrogen Sulfide SCHEMBL28780209 | 0.98 | ACE (0.62) | ACERENKDM4EF2LMNA | |
| Water SCHEMBL11063395 | 0.98 | ACE (0.62) | ACERENKDM4EF2LMNA | |
| Hydrogen Sulfide SCHEMBL28780210 | 0.98 | ACE (0.62) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4706663-A2 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | Trustees Of Tufts College (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TUFTS COLLEGE (US) | 2025-12-04 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | claimed |
| CN-117729942-A | Methods for increasing efficacy of ADAM 9-targeted immunoconjugates in the treatment of cancer | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117730098-A | Treatment of cancer in patients with soluble FR-alpha | 伊缪诺金公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4304660-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ImmunoGen, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-1323730-B1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | BIOKINE THERAPEUTICS LTD (IL) | 2010-04-21 | — | — | EP | claimed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | claimed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | ACE 3845/4885REN 2024/4885KDM4E 3800/4885 |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | ACE 1733/4885REN 1390/4885KDM4E 4330/4885 |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | ACE 278/4885REN 3757/4885KDM4E 3496/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | ACE 187/4885REN 2059/4885KDM4E 3258/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | ACE 1733/4885REN 1390/4885KDM4E 4330/4885 |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMB1 | ACE 84/4885REN 739/4885KDM4E 1202/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | ACE 4766/4885REN 4531/4885KDM4E 3874/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | ACE 2255/4885REN 535/4885KDM4E 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.